Prevenox Plus versus original Prevenox: Comparison of effects in healthy volunteers

Prevenox Plus versus original Prevenox: Comparison of effects in healthy volunteers - PrevP/Prev

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

RPCEC

Registry ID

RPCEC00000456

Enrollment

Registered

2025-03-07

Start date

2025-03-27

Completion date

Unknown

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

Group 1 Prevenox Plus (Experimental): Prevenox Plus (5 mg), 1 tablet by oral route, twice a day (lunch and dinner), for 12 weeks. Group 2 Prevenox (Experimental): Prevenox (5 mg), 1 tablet by oral

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Healthy subjects of both sexes, aged between 20 and 60 years, who agree to participate in the study after signing their informed consent will be recruited into the study.

Exclusion criteria

Exclusion criteria: Subjects with: 1. Dyslipidemia 2. High blood pressure 3. Diabetes mellitus 4. Thyroid disorders. 5. History of vascular diseases (coronary, cerebrovascular, peripheral) 6. Major surgery in the six months prior to the start of the study. 7. History of liver or kidney failure. 8. Diagnosed neoplasms. 9. Alcoholism. 10. Consumption of policosanol or another lipid-lowering agent in a period of six months prior to the study. 11. Psychiatric problems that limit their participation. 12. Usual medical history of allergy to medications or any other special condition that, in the doctor's opinion, puts your health and life at risk during the study.

Design outcomes

Secondary

Measure	Time frame
Secondary response variables: 1. Total cholesterol. Measurement time: At baseline and 12 weeks of treatment 2. HDL-C. Measurement time: At baseline and 12 weeks of treatment 3. Tryglicerides. Measurement time: At baseline and 12 weeks of treatment Collateral response variables: 1. Coagulation time. Measurement time: At baseline and 12 weeks of treatment 2. Bleeding time. Measurement time: At baseline and 12 weeks of treatment 3. Prothrombin time. Measurement time: At baseline and 12 weeks of treatment	—

Measure

Time frame

Secondary response variables: 1. Total cholesterol. Measurement time: At baseline and 12 weeks of treatment 2. HDL-C. Measurement time: At baseline and 12 weeks of treatment 3. Tryglicerides. Measurement time: At baseline and 12 weeks of treatment Collateral response variables: 1. Coagulation time. Measurement time: At baseline and 12 weeks of treatment 2. Bleeding time. Measurement time: At baseline and 12 weeks of treatment 3. Prothrombin time. Measurement time: At baseline and 12 weeks of treatment

—

Primary

Measure	Time frame
LDL.C. Measurement time: At baseline and 12 weeks of treatment	—

Countries

Cuba

Contacts

Public ContactIvan Rodriguez Cortina

Medical-Surgical Research Center (CIMEQ)

ivan.rodriguez@infomed.sld.cu

Outcome results

None listed

Source: RPCEC (via WHO ICTRP) · Data processed: Aug 25, 2026